The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings

G. Cavaletti; D. R. Cornblath; I. S. J. Merkies; T. J. Postma; E. Rossi; B. Frigeni; P. Alberti; J. Bruna; R. Velasco; A. A. Argyriou; H. P. Kalofonos; D. Psimaras; D. Ricard; A. Pace; E. Galie; C. Briani; C. Dalla Torre; C. G. Faber; R. I. Lalisang; W. Boogerd; D. Brandsma; S. Koeppen; J. Hense; D. Storey; S. Kerrigan; A. Schenone; S. Fabbri; M. G. Valsecchi

doi:10.1093/annonc/mds329

The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings

G. Cavaletti^*, D. R. Cornblath, I. S. J. Merkies, T. J. Postma, E. Rossi, B. Frigeni, P. Alberti, J. Bruna, R. Velasco, A. A. Argyriou, H. P. Kalofonos, D. Psimaras, D. Ricard, A. Pace, E. Galie, C. Briani, C. Dalla Torre, C. G. Faber, R. I. Lalisang, W. BoogerdD. Brandsma, S. Koeppen, J. Hense, D. Storey, S. Kerrigan, A. Schenone, S. Fabbri, M. G. Valsecchi

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

186 Citations (Web of Science)

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting complication of cancer treatment. Thus far, the impact of CIPN has not been studied in a systematic clinimetric manner. The objective of the study was to select outcome measures for CIPN evaluation and to establish their validity and reproducibility in a cross-sectional multicenter study. After literature review and a consensus meeting among experts, face/content validity were obtained for the following selected scales: the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), the Total Neuropathy Score clinical version (TNSc), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) group sensory sumscore (mISS), the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, and CIPN20 quality-of-life measures. A total of 281 patients with stable CIPN were examined. Validity (correlation) and reliability studies were carried out. Good inter-/intra-observer scores were obtained for the TNSc, mISS, and NCI-CTC sensory/motor subscales. Test-retest values were also good for the EORTC QLQ-C30 and CIPN20. Acceptable validity scores were obtained through the correlation among the measures. Good validity and reliability scores were demonstrated for the set of selected impairment and quality-of-life outcome measures in CIPN. Future studies are planned to investigate the responsiveness aspects of these measures.

Original language	English
Pages (from-to)	454-462
Journal	Annals of Oncology
Volume	24
Issue number	2
DOIs	https://doi.org/10.1093/annonc/mds329
Publication status	Published - Feb 2013

Keywords

assessment
chemotherapy
clinimetrics
peripheral neuropathy
reliability
validity

Access to Document

10.1093/annonc/mds329

Cite this

Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Rossi, E., Frigeni, B., Alberti, P., Bruna, J., Velasco, R., Argyriou, A. A., Kalofonos, H. P., Psimaras, D., Ricard, D., Pace, A., Galie, E., Briani, C., Dalla Torre, C., Faber, C. G., Lalisang, R. I., ... Valsecchi, M. G. (2013). The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Annals of Oncology, 24(2), 454-462. https://doi.org/10.1093/annonc/mds329

@article{f01fd2e78c8d4aee94aa05d929ed599c,

title = "The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings",

abstract = "Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting complication of cancer treatment. Thus far, the impact of CIPN has not been studied in a systematic clinimetric manner. The objective of the study was to select outcome measures for CIPN evaluation and to establish their validity and reproducibility in a cross-sectional multicenter study. After literature review and a consensus meeting among experts, face/content validity were obtained for the following selected scales: the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), the Total Neuropathy Score clinical version (TNSc), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) group sensory sumscore (mISS), the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, and CIPN20 quality-of-life measures. A total of 281 patients with stable CIPN were examined. Validity (correlation) and reliability studies were carried out. Good inter-/intra-observer scores were obtained for the TNSc, mISS, and NCI-CTC sensory/motor subscales. Test-retest values were also good for the EORTC QLQ-C30 and CIPN20. Acceptable validity scores were obtained through the correlation among the measures. Good validity and reliability scores were demonstrated for the set of selected impairment and quality-of-life outcome measures in CIPN. Future studies are planned to investigate the responsiveness aspects of these measures.",

keywords = "assessment, chemotherapy, clinimetrics, peripheral neuropathy, reliability, validity",

author = "G. Cavaletti and Cornblath, {D. R.} and Merkies, {I. S. J.} and Postma, {T. J.} and E. Rossi and B. Frigeni and P. Alberti and J. Bruna and R. Velasco and Argyriou, {A. A.} and Kalofonos, {H. P.} and D. Psimaras and D. Ricard and A. Pace and E. Galie and C. Briani and {Dalla Torre}, C. and Faber, {C. G.} and Lalisang, {R. I.} and W. Boogerd and D. Brandsma and S. Koeppen and J. Hense and D. Storey and S. Kerrigan and A. Schenone and S. Fabbri and Valsecchi, {M. G.}",

year = "2013",

month = feb,

doi = "10.1093/annonc/mds329",

language = "English",

volume = "24",

pages = "454--462",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "2",

}

Cavaletti, G, Cornblath, DR, Merkies, ISJ, Postma, TJ, Rossi, E, Frigeni, B, Alberti, P, Bruna, J, Velasco, R, Argyriou, AA, Kalofonos, HP, Psimaras, D, Ricard, D, Pace, A, Galie, E, Briani, C, Dalla Torre, C, Faber, CG , Lalisang, RI, Boogerd, W, Brandsma, D, Koeppen, S, Hense, J, Storey, D, Kerrigan, S, Schenone, A, Fabbri, S & Valsecchi, MG 2013, 'The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings', Annals of Oncology, vol. 24, no. 2, pp. 454-462. https://doi.org/10.1093/annonc/mds329

TY - JOUR

T1 - The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings

AU - Cavaletti, G.

AU - Cornblath, D. R.

AU - Merkies, I. S. J.

AU - Postma, T. J.

AU - Rossi, E.

AU - Frigeni, B.

AU - Alberti, P.

AU - Bruna, J.

AU - Velasco, R.

AU - Argyriou, A. A.

AU - Kalofonos, H. P.

AU - Psimaras, D.

AU - Ricard, D.

AU - Pace, A.

AU - Galie, E.

AU - Briani, C.

AU - Dalla Torre, C.

AU - Faber, C. G.

AU - Lalisang, R. I.

AU - Boogerd, W.

AU - Brandsma, D.

AU - Koeppen, S.

AU - Hense, J.

AU - Storey, D.

AU - Kerrigan, S.

AU - Schenone, A.

AU - Fabbri, S.

AU - Valsecchi, M. G.

PY - 2013/2

Y1 - 2013/2

N2 - Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting complication of cancer treatment. Thus far, the impact of CIPN has not been studied in a systematic clinimetric manner. The objective of the study was to select outcome measures for CIPN evaluation and to establish their validity and reproducibility in a cross-sectional multicenter study. After literature review and a consensus meeting among experts, face/content validity were obtained for the following selected scales: the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), the Total Neuropathy Score clinical version (TNSc), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) group sensory sumscore (mISS), the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, and CIPN20 quality-of-life measures. A total of 281 patients with stable CIPN were examined. Validity (correlation) and reliability studies were carried out. Good inter-/intra-observer scores were obtained for the TNSc, mISS, and NCI-CTC sensory/motor subscales. Test-retest values were also good for the EORTC QLQ-C30 and CIPN20. Acceptable validity scores were obtained through the correlation among the measures. Good validity and reliability scores were demonstrated for the set of selected impairment and quality-of-life outcome measures in CIPN. Future studies are planned to investigate the responsiveness aspects of these measures.

AB - Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting complication of cancer treatment. Thus far, the impact of CIPN has not been studied in a systematic clinimetric manner. The objective of the study was to select outcome measures for CIPN evaluation and to establish their validity and reproducibility in a cross-sectional multicenter study. After literature review and a consensus meeting among experts, face/content validity were obtained for the following selected scales: the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), the Total Neuropathy Score clinical version (TNSc), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) group sensory sumscore (mISS), the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, and CIPN20 quality-of-life measures. A total of 281 patients with stable CIPN were examined. Validity (correlation) and reliability studies were carried out. Good inter-/intra-observer scores were obtained for the TNSc, mISS, and NCI-CTC sensory/motor subscales. Test-retest values were also good for the EORTC QLQ-C30 and CIPN20. Acceptable validity scores were obtained through the correlation among the measures. Good validity and reliability scores were demonstrated for the set of selected impairment and quality-of-life outcome measures in CIPN. Future studies are planned to investigate the responsiveness aspects of these measures.

KW - assessment

KW - chemotherapy

KW - clinimetrics

KW - peripheral neuropathy

KW - reliability

KW - validity

U2 - 10.1093/annonc/mds329

DO - 10.1093/annonc/mds329

M3 - Article

C2 - 22910842

SN - 0923-7534

VL - 24

SP - 454

EP - 462

JO - Annals of Oncology

JF - Annals of Oncology

IS - 2

ER -